Autologous B7-H3 Chimeric Antigen Receptor T Cells therapy (NIH)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameAutologous B7-H3 Chimeric Antigen Receptor T Cells therapy (NIH)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionT lymphocyte replacementsAnti-CD276

TargetsCD276 antigen

Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute

Inactive CompaniesN/A

Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine

Inactive IndicationsN/A

Other Information

ATC CodeN/A